The system for testing pharmaceuticals in the US relies on contractors adhering to strict guidelines. But one of them chose profits over protocols.
THE EMAIL THAT Joe Hagood received in August 2017 was vague and brief, but too unsettling to ignore.
A shocking story from the US. For us, accounts like this raise a contentious question: Should clinical trials only be conducted by not-for-profit bodies? Is the status-quo hampered by too compromised by surmountable conflicts of interest? We have included links to 18 related items.
The email contained no evidence to support this jarring allegation, so Hagood thought it wise to tread cautiously; he worried that Bruinekool might be a disgruntled employee out to make trouble. In his reply, he thanked her for the tip and politely encouraged her to reach him on his cell phone.
A week passed before Bruinekool called. As soon as he picked up the phone, he could tell by her voice that she was genuinely frightened. A 36-year-old mother of three, including a daughter who would soon be off to college, Bruinekool could not afford to lose her $17-an-hour position at Mid-Columbia Research, the center where she worked. She asked for assurances that Medpace would never reveal her identity to her company’s owner, whom she knew had a vindictive streak.